ArticleJournal of veterinary internal medicine2026
Circulating renin-angiotensin-aldosterone system markers in cats with non-hypertensive chronic kidney disease or systemic arterial hypertension.
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mass spectrometry-based urinary proteomic analysis in feline chronic kidney disease.Physiological reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundInformation on the classical and alternative circulating renin-angiotensin-aldosterone systems (RAAS) in cats with non-hypertensive chronic kidney disease (NHT-CKD) or systemic arterial hypertension (SAH) is limited. Age and diet affect the RAAS. HYPOTHESIS/
objectivesTo compare serum equilibrium concentrations of angiotensin peptides and aldosterone in healthy cats and cats with NHT-CKD or untreated SAH, and to evaluate changes in these concentrations in hypertensive cats administered amlodipine. ANIMALS: Client-owned cats with NHT-CKD (serum creatinine ≥ 1.6 mg/dL, systolic blood pressure [SBP] < 160 mmHg; n = 17), SAH (SBP ≥ 160 mmHg or ≥ 150 mmHg with hypertensive ocular lesions; n = 6), or normal SBP (<140 mmHg) and kidney function (n = 17).
methodsProspective, single-center, observational study. Cats underwent indirect SBP measurement and clinicopathologic analyses. Serum was obtained contemporaneously in all cats, and after 2-4 weeks of amlodipine therapy in hypertensive cats, for evaluation of angiotensin I, II, III, IV, 1-5, and 1-7, and aldosterone.
resultsAdjusting for diet, age, or both modified the conclusions of statistical comparisons for several variables. Mean serum angiotensin I, II, and III concentrations were lower in cats with untreated SAH vs healthy controls across unadjusted and diet-, age-, or both diet- and age-adjusted linear mixed models (geometric mean [95% CI] angiotensin I, 9.02 [3.05-26.62] vs 29.78 [21.15-41.94] pmol/L; angiotensin II, 33.63 [12.25-92.26] vs 124.24 [90.52-170.51] pmol/L; angiotensin III, 1.56 [0.88-2.79] vs 7.96 [5.35-11.86] pmol/L; all P ≤ .038). Controlling for diet but not age, angiotensin II (P = .043) and III (P = .019) were also lower in cats with NHT-CKD vs controls. All angiotensin peptides, except for angiotensin IV, significantly increased in hypertensive cats during amlodipine therapy. Serum aldosterone did not differ between groups, or before and after amlodipine in hypertensive cats. CONCLUSIONS AND CLINICAL IMPORTANCE: Evidence of circulating RAAS activation in cats with NHT-CKD or untreated SAH was not found.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.